Kisspeptin-10 Research Peptide

Kisspeptin began life as a cancer gene. In 1996 Danny Welch’s laboratory at Penn State’s Hershey campus was studying melanoma cells that lost their ability to spread after a copy of human chromosome 6 was introduced. The gene they pinned down was named KiSS-1, a nod to Hershey’s Kisses chocolates made in the same town, with the capital “SS” standing for suppressor sequence.

Five years later, in 2001, the protein product was traced. A team at Takeda isolated a 54-residue amidated peptide from human placenta, showed it was the natural partner of an orphan receptor and called it metastin, after its anti-metastatic activity. Other groups described the same peptide and its shorter relatives as kisspeptins, and the receptor, first catalogued as GPR54, is now usually listed as KISS1R. Kisspeptin-10 corresponds to the last ten residues of that 54-residue chain, which is why it is also labelled metastin 45–54.

The reproductive story arrived suddenly. In 2003 two independent teams, led by Nicolas de Roux in France and Stephanie Seminara in Boston, reported families in which children failed to go through puberty because of loss-of-function changes in the GPR54 gene. The hypothalamus and pituitary looked structurally normal, yet the signal that starts the reproductive axis was missing. Mice engineered to lack the receptor showed the same picture.

That result reframed the whole field. Kisspeptin was no longer just a metastasis curiosity; it sat directly upstream of gonadotropin-releasing hormone, the master signal for luteinising hormone and follicle-stimulating hormone. Later work placed kisspeptin-producing neurons in the arcuate nucleus alongside neurokinin B and dynorphin, the so-called KNDy cells, now widely studied as part of the circuit that sets the rhythm of GnRH pulses.

Kisspeptin-54, -14, -13 and -10 all end in the same C-terminal decapeptide, finished with an arginine–phenylalanine amide. That shared tail places them in the RF-amide peptide family and carries the receptor-binding information, so Kisspeptin-10 is regarded as the minimal sequence with full intrinsic activity at KISS1R. Its small size makes it straightforward to make, purify and characterise, which is a big part of its popularity in receptor work.

One property shapes experimental design more than any other. In juvenile male rhesus monkeys, a continuous four-day infusion of Kisspeptin-10 produced an initial burst of luteinising hormone followed by a steep fall, even though the peptide was still present. GnRH itself could still trigger a response, which showed the receptor had become desensitised. Pulsed versus continuous exposure is therefore a central variable in kisspeptin studies.

The first human data came from Waljit Dhillo’s group in London, who reported in 2005 that kisspeptin-54 raised luteinising hormone in healthy men. Kisspeptin-10 itself was studied in men by an Edinburgh-led team in 2011. A single intravenous bolus produced a rapid rise in LH that grew with bolus size up to a point, after which the response became smaller. During longer infusions, deconvolution analysis showed more frequent and larger LH pulses, and testosterone rose.

Findings in women added a twist. Studies in London and Boston found that the LH response depended heavily on the phase of the menstrual cycle, being clear in the pre-ovulatory and luteal phases but much less consistent in the early follicular phase. The Boston authors interpreted this as a sign that natural kisspeptin tone varies across the cycle, a useful lesson for anyone comparing results between models.

Kisspeptin’s most publicised clinical research has used the longer kisspeptin-54, not the decapeptide. In a 2014 Journal of Clinical Investigation paper, Imperial College researchers gave kisspeptin-54 to 53 women undergoing IVF in place of the usual hormone trigger, and 51 produced mature eggs. The idea behind the design is that kisspeptin does not mimic luteinising hormone directly; it prompts the brain to release GnRH, so the surge that follows comes from the pituitary itself and is shorter-lived than the exposure produced by the conventional trigger. Because kisspeptin acts through the body’s own GnRH system and clears quickly, follow-up studies examined it in women at high risk of ovarian hyperstimulation. These are clinical research findings for kisspeptin-54; Kisspeptin-10 remains the shorter fragment favoured in receptor and pulse-pattern experiments.